BioLife Solutions Inc
BLFS24.900USD
-0.510-2.01%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
1.19BCap. mercado
PérdidaP/E TTM
Más Datos de BioLife Solutions Inc Compañía
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Información de BioLife Solutions Inc
Símbolo de cotizaciónBLFS
Nombre de la empresaBioLife Solutions Inc
Fecha de salida a bolsaNov 22, 1989
Director ejecutivoDe Greef (Roderick)
Número de empleados159
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 22
DirecciónSuite 310
CiudadBOTHELL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal98021
Teléfono14254011400
Sitio Webhttps://www.biolifesolutions.com/
Símbolo de cotizaciónBLFS
Fecha de salida a bolsaNov 22, 1989
Director ejecutivoDe Greef (Roderick)
Ejecutivos de BioLife Solutions Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
252.89K
-0.21%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
150.11K
-0.28%
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
98.49K
-0.31%
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
81.02K
-31.81%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
68.75K
-30.38%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
49.99K
-0.43%
Mr. Joydeep Goswami
Mr. Joydeep Goswami
Independent Director
Independent Director
38.11K
-7.30%
Sean Werner
Sean Werner
Chief Technology Officer
Chief Technology Officer
25.93K
-0.42%
Ms. Amy Duross
Ms. Amy Duross
Lead Independent Director
Lead Independent Director
13.81K
-42.00%
Ms. Catherine (Cathy) Coste, CPA
Ms. Catherine (Cathy) Coste, CPA
Independent Director
Independent Director
5.70K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Aby J. Mathew, Ph.D.
Dr. Aby J. Mathew, Ph.D.
Chief Scientific Officer, Executive Vice President
Chief Scientific Officer, Executive Vice President
252.89K
-0.21%
Ms. Karen A. Foster
Ms. Karen A. Foster
Chief Quality and Operations Officer
Chief Quality and Operations Officer
150.11K
-0.28%
Mr. Todd Berard
Mr. Todd Berard
Chief Commercial Officer
Chief Commercial Officer
98.49K
-0.31%
Mr. Roderick De Greef
Mr. Roderick De Greef
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
81.02K
-31.81%
Mr. Troy Wichterman
Mr. Troy Wichterman
Chief Financial Officer
Chief Financial Officer
68.75K
-30.38%
Ms. Sarah Aebersold
Ms. Sarah Aebersold
Chief Human Resources Officer
Chief Human Resources Officer
49.99K
-0.43%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Product Revenue-Cell processing
22.90M
90.08%
Rental Revenue- Evo and thaw
1.68M
6.59%
Product Revenue- Evo and thaw
811.00K
3.19%
Service Revenue-Evo and thaw
36.00K
0.14%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product Revenue-Cell processing
22.90M
90.08%
Rental Revenue- Evo and thaw
1.68M
6.59%
Product Revenue- Evo and thaw
811.00K
3.19%
Service Revenue-Evo and thaw
36.00K
0.14%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Casdin Capital, LLC
12.37%
BlackRock Institutional Trust Company, N.A.
10.60%
T. Rowe Price Investment Management, Inc.
8.45%
Invesco Advisers, Inc.
7.22%
The Vanguard Group, Inc.
6.15%
Otro
55.21%
Accionistas
Accionistas
Proporción
Casdin Capital, LLC
12.37%
BlackRock Institutional Trust Company, N.A.
10.60%
T. Rowe Price Investment Management, Inc.
8.45%
Invesco Advisers, Inc.
7.22%
The Vanguard Group, Inc.
6.15%
Otro
55.21%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
49.20%
Investment Advisor/Hedge Fund
34.12%
Hedge Fund
15.54%
Research Firm
2.32%
Individual Investor
2.00%
Pension Fund
1.60%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.08%
Insurance Company
0.03%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
402
49.86M
109.33%
-743.44K
2025Q3
418
50.60M
112.73%
+431.43K
2025Q2
417
51.14M
109.98%
+2.32M
2025Q1
412
48.78M
108.79%
-2.89M
2024Q4
397
47.68M
109.40%
+879.99K
2024Q3
391
46.15M
113.67%
-1.38M
2024Q2
371
47.55M
108.21%
+1.88M
2024Q1
363
45.48M
113.98%
-6.15M
2023Q4
383
46.46M
115.88%
+36.24K
2023Q3
386
44.68M
106.82%
+2.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Casdin Capital, LLC
6.71M
14%
-1.00M
-12.97%
Aug 15, 2025
BlackRock Institutional Trust Company, N.A.
5.08M
10.61%
+12.43K
+0.25%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
4.25M
8.86%
+2.90M
+215.04%
Jun 30, 2025
Invesco Advisers, Inc.
3.46M
7.22%
+126.62K
+3.80%
Jun 30, 2025
The Vanguard Group, Inc.
2.89M
6.03%
+93.13K
+3.33%
Jun 30, 2025
State Street Investment Management (US)
1.41M
2.94%
-24.84K
-1.73%
Jun 30, 2025
Fred Alger Management, LLC
1.25M
2.61%
-285.09K
-18.60%
Jun 30, 2025
MFS Investment Management
1.10M
2.3%
+337.42K
+44.13%
Jun 30, 2025
Rockefeller Capital Management
1.03M
2.14%
+62.16K
+6.45%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco S&P SmallCap Health Care ETF
0.66%
Invesco S&P SmallCap 600 Pure Growth ETF
0.62%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Zacks Small/Mid Cap ETF
0.41%
iShares Micro-Cap ETF
0.2%
State Street SPDR S&P 600 Small Cap Growth ETF
0.15%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.14%
iShares S&P Small-Cap 600 Growth ETF
0.14%
iShares ESG Select Screened S&P Small-Cap ETF
0.09%
Ver más
Invesco S&P SmallCap Health Care ETF
Proporción0.66%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción0.62%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.52%
Zacks Small/Mid Cap ETF
Proporción0.41%
iShares Micro-Cap ETF
Proporción0.2%
State Street SPDR S&P 600 Small Cap Growth ETF
Proporción0.15%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.15%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proporción0.14%
iShares S&P Small-Cap 600 Growth ETF
Proporción0.14%
iShares ESG Select Screened S&P Small-Cap ETF
Proporción0.09%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de BioLife Solutions Inc?
Los cinco principales accionistas de BioLife Solutions Inc son:
Casdin Capital, LLC posee 6.71M acciones, lo que representa el 14.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.08M acciones, lo que representa el 10.61% del total de acciones.
T. Rowe Price Investment Management, Inc. posee 4.25M acciones, lo que representa el 8.86% del total de acciones.
Invesco Advisers, Inc. posee 3.46M acciones, lo que representa el 7.22% del total de acciones.
The Vanguard Group, Inc. posee 2.89M acciones, lo que representa el 6.03% del total de acciones.
Casdin Capital, LLC posee 6.71M acciones, lo que representa el 14.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.08M acciones, lo que representa el 10.61% del total de acciones.
T. Rowe Price Investment Management, Inc. posee 4.25M acciones, lo que representa el 8.86% del total de acciones.
Invesco Advisers, Inc. posee 3.46M acciones, lo que representa el 7.22% del total de acciones.
The Vanguard Group, Inc. posee 2.89M acciones, lo que representa el 6.03% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de BioLife Solutions Inc?
Los tres principales tipos de accionista de BioLife Solutions Inc son:
Casdin Capital, LLC
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Investment Management, Inc.
Casdin Capital, LLC
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Investment Management, Inc.
¿Cuántas instituciones poseen acciones de BioLife Solutions Inc (BLFS)?
A fecha de 2025Q4, 402 instituciones poseen acciones de BioLife Solutions Inc, con un valor de mercado combinado de aproximadamente 49.86M, lo que representa el 109.33% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -3.40%.
¿Cuál es la mayor fuente de ganancias de BioLife Solutions Inc?
El FY2025Q2, el segmento empresarial Product Revenue-Cell processing generó la ganancia más alta para BioLife Solutions Inc, ascendiendo a 22.90M y representando el 90.08% de la ganancia total.
